Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials-Reference-Cited by-同舟云学术

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials

Published:2021-09-27 Issue:12 Volume:23 Page:2785-2794
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Araki Eiichi¹^ORCID,Terauchi Yasuo²^ORCID,Watada Hirotaka³^ORCID,Deenadayalan Srikanth⁴,Christiansen Erik⁴,Horio Hiroshi⁵,Kadowaki Takashi⁶

Affiliation:

1. Department of Metabolic Medicine, Faculty of Life Sciences Kumamoto University Kumamoto Japan

2. Yokohama City University Yokohama Japan

3. Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan

4. Novo Nordisk A/S Søborg Denmark

5. Novo Nordisk Pharma Ltd Tokyo Japan

6. Toranomon Hospital Tokyo Japan

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14536

Reference24 articles.

1. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

2. Pharmaceutical and Medical Devices Agency Japan.Rybelsus® prescribing information 2020.https://www.pmda.go.jp/files/000208192.pdf. Accessed 14 September 2021.

3. European Medicines Agency.Rybelsus® summary of product characteristics 2020.https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf. Accessed 13 September 2021.

4. US Food and Drug Administration.Rybelsus® prescribing information 2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf. Accessed 13 September 2021.

5. Japanese Clinical Practice Guideline for Diabetes 2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus;Diabetology International;2024-05-30

2. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2023-10-12

3. Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus;Problems of Endocrinology;2023-05-11

4. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2022-12-19

5. Regulation of feeding and therapeutic application of bioactive peptides;Pharmacology & Therapeutics;2022-11